Octadec-9-enyl 2,3-dihydroxypropanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Octadec-9-enyl 2,3-dihydroxypropanoate
• 化学式: C₂₁H₄₀O₄
• 分子量: 356.5
• InChiKey: JPJYKWFFJCWMPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  25
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS<br/>[FR] PHASE LYOTROPE D'UNE CHAINE HYDROCARBURE A TETE A BASE D'UREE, DE GLYCERAT ET D'HYDROXYAMIDE FORMANT DES TENSIOACTIFS
  申请人：DBL AUSTRALIA PTY LTD

  公开号：WO2004022530A1

  公开（公告）日：2004-03-18

  The invention provides a compound containing a head group based on urea, glycerol or glycerate and a tail selected from the group consisting of a branched alkyl chain, a branched alkyloxy chain or an alkenyl chain. The compounds may be used as surfactants to form a lyotropic phase that is stable in excess polar solution.

  该发明提供了一种含有基于尿素、甘油或甘酸的头基以及选择自支链烷基链、支链烷氧基链或烯基链的尾基的化合物。这些化合物可用作表面活性剂，形成在过量极性溶液中稳定的亮度相。
• Compositions and methods for delivery of biologically active agents
  申请人：Khoo Shui-Mei

  公开号：US20070108405A1

  公开（公告）日：2007-05-17

  The present invention provides methods and compositions for the delivery of a biologically active agent to a biological system. The compositions include the active agent and a lyotropic phase and release of the active agent to the biological system is modified by the lyotropic phase.

  本发明提供了将生物活性物质传递到生物系统的方法和组合物。这些组合物包括活性物质和亲疏水相，而亲疏水相可以调节活性物质在生物系统中的释放。
• ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE
  申请人：Zysis Limited

  公开号：US20140044786A1

  公开（公告）日：2014-02-13

  An orally deliverable pharmaceutical composition provides controlled release of aripiprazole. The composition includes a therapeutically effective amount of aripiprazole and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in the specification.

  一种口服药物组合物提供了对阿立哌唑的控制释放。该组合物包括治疗有效量的阿立哌唑和至少一种药用可接受的辅料。该发明的组合物可能展示规范中定义的一个或多个释放剖面。
• Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：US10722585B2

  公开（公告）日：2020-07-28

  Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

  公开了一种药物组合物，它包括a) 至少一种山梨糖醇不饱和脂肪酸酯，其极性头具有至少两个或两个以上的 -OH（羟基）基团； b) 至少一种磷脂； c) 至少一种液晶硬化剂，其不含可电离基团，具有 15 至 40 个碳原子的三酰基或疏水分子中的碳环结构；d) 至少一种作为药理活性物质的 GnRH（促性腺激素释放激素）类似物，其中所述脂质预浓缩物在无水性流体时以液相存在，在有水性流体时形成液晶。该药物组合物可增强药理活性物质 GnRH 类似物的持续释放。
• Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
  申请人：Tris Pharma, Inc.

  公开号：US11337919B2

  公开（公告）日：2022-05-24

  An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

  本发明提供了一种可口服的药物粉末组合物，该组合物可形成具有至少两个触发脉冲的胃保留型 RAFT。该组合物至少包含：(a) 至少一种速释脉冲释放形式的药物；(b) 至少一种延迟触发释放形式的药物；(c) 至少一种无毒气体发生剂和 (d) 一种 RAFT 系统，其中，口服后，该组合物提供一种自组装的胃保留 RAFT，其中夹带有 (a) 和 (b) 中的至少一种药物以及由无毒气体发生剂在原位产生的气体、从而提供一种具有双脉冲系统的浮动胃保留型RAFT，其中至少第二个脉冲是触发脉冲，并将至少一种药物保留在胃中至少约3小时，前提是该组合物不包括γ-羟丁酸及其盐类、水合物、同系物或溶解物或其复合物。